CAR architecture has evolved through four generations. The first relied solely on CD3ζ and lacked potency. Second-generation receptors added either CD28 or 4-1BB costimulation, striking a balance ...

A new paper published today in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel synthetic ligand that activates the Notch signaling pathway, a key ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...

Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response ...

A cancer drug class best known for attacking tumors may also help your immune system remember them better. Researchers at Georgetown University’s Lombardi Comprehensive Cancer Center report that ...

Our immune system relies on T cells to fight infections. But T cells don't just show up and react—first, they train, get a ...

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively ...

Cancer tumors hijack the vagus nerve to communicate with the brain, triggering a hormonal response that suppresses the immune system.